The advent and advancement of T cell therapy, especially chimeric antigen receptor (CAR)-modified T cells, has demonstrated therapeutic potential in treating previously treatment-resistant tumors. However, few CAR targets are absolutely tumor-specific, resulting in “on-target, off-tumor” toxicities that can be severe.
Researchers in the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist have found a new way to ensure that engineered T cells can reliably discriminate between normal and malignant cells. Read more . . .